


PHARMACEUTICAL 2023

Edgewise Therapeutics Inc. Rank 27 of 446









RealRate

PHARMACEUTICAL 2023



Edgewise Therapeutics Inc. Rank 27 of 446

The relative strengths and weaknesses of Edgewise Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edgewise Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Edgewise Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 230% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	356,999
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,585
Liabilities, Non-Current	3,800
Other Assets	1,569
Other Compr. Net Income	-841
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	4,018
Property and Equipment	8,533
Research and Development	54,032
Selling, General and Administrative Expense	17,626

Output Variable	Value in 1000 USD
Assets	367,101
Liabilities	20,385
Expenses	71,658
Revenues	4,018
Stockholders Equity	346,716
Net Income	-67,640
Comprehensive Net Income	-68,060
Economic Capital Ratio	273%

